EAE. A. Artyomova

E. A. Artyomova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Artyomova has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recombinant human adenovirus expressing a modified hemagglutinin induces cross-protection against heterologous influenza viruses A/H1N1

    by E.D. Avdonina, D.N. Shcherbinin, A.S. Bandelyuk, E.A. Evgrafova, K.A. Pervoykina, L.V. Verkhovskaya, M.M. Shmarov, A.L. Gintsburg

    Рекомбинантный аденовирус человека, экспрессирующий модифицированный ген гемагглютинина, индуцирует перекрестную защиту от гетерологичных вирусов

  • Open Access

    Genetic model of motor neuron disease in B6SJL-Tg mice: new data on the dynamics of motor symptoms and immunohistochemical manifestations of the neurodegenerative process

    by А. V. Stavrovskaya, D. N. Voronkov, E. A. Artyomova, B. V. Belugin, М. М. Shmarov, N. G. Yamshchikova, А. S. Gushchina, А. С. Ольшанский, B. S. Naroditskiy, S. N. Illarioshkin

    Introduction. Over the past several decades, the study of mutations associated with motor neuron disease has led to the development of a number of transgenic animal models of motor neuron disease. One of the causes of the familial form of this disorder is mutations in the gene encoding Cu/Zn superoxide dismutase 1. The B6SJL-Tg (SOD1*G93A) mouse strain expresses a mutant form of human superoxide dismutase 1. Aim of study. To assess motor functions, dynamics of survival, and morphological changes in the spinal cord of transgenic B6SJL-Tg (SOD1*G93A) mice. Material and methods. In total, 31 animals have been studied. Starting from the age of 22 weeks, once every two weeks, the “open field” and “beam walking” motor tests were performed. The morphological changes in the spinal cord were evaluated at intermediate (26–35 weeks) and late stages (40–45 weeks). Neuronal proteins NeuN and PGP9.5, gliofibrillar protein, cyclonucleotide phosphatase (a marker of oligodendroglia) and a marker protein of microglia IBA1 were detected by immunohistochemistry; antibodies MTC02 to the outer membrane protein were used to detect mitochondria. Results. Motor problems appeared at the age of 24–26 weeks and steadily progressed; one could see consistent paresis of the hindlimbs, then the forelimbs, which was accompanied by general hypotrophy of the animals. There was a greater variability in the timing of symptom onset and life expectancy in males compared to females. The neurodegenerative process with damage to motor neurons was accompanied by the activation of micro- and astroglia. A sharp decrease in immunoreactivity to the mitochondrial marker MTC02 was found. Conclusion. The obtained results demonstrate new details of the development of a complex of motor and pathomorphological changes characteristic of motor neuron disease in B6SJL-Tg (SOD1*G93A) mice. Clarification of the fine dynamics of the neurodegenerative process in these animals is of great importance for monitoring the course of the disease during preclinical trials of new drugs and methods of gene therapy.


  • Open Access

    Protecting Mice from H7 Avian Influenza Virus by Immunisation with a Recombinant Adenovirus Encoding Influenza A Virus Conserved Antigens

    by E. S. Sedova, L. V. Verkhovskaya, E. A. Artemova, D. N. Shcherbinin, A. A. Lysenko, I. A. Rudneva, A. V. Lyashko, S. A. Alekseeva, I. B. Esmagambetov, T. A. Timofeeva, et al.

    Influenza is a highly contagious disease that causes annual epidemics and occasional pandemics. Birds are believed to be the source of newly emerging pandemic strains, including highly pathogenic avian influenza viruses of the subtype H7. The aim of the study: to evaluate the ability of the recombinant human adenovirus, serotype 5, which expresses genes of influenza A highly conserved antigens (ion channel M2 and nucleoprotein NP), to provide protection to laboratory mice against infection with a lethal dose of avian influenza virus, subtype H7. To achieve this goal, it was necessary to adapt influenza A virus, subtype H7 for reproduction in the lungs of mice, to characterise it, and to use it for evaluation of the protective properties of the recombinant adenovirus. Materials and methods: avian influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) was adapted for reproduction in the lungs of mice by repeated passages. The adapted strain was sequenced and assessed using hemagglutination test, EID50 and LD50 for laboratory mice. BALB/c mice were immunised once with Ad5-tet-M2NP adenovirus intranasally, and 21 days after the immunisation they were infected with a lethal dose (5 LD50) of influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) in order to assess the protective properties of the recombinant adenovirus. The level of viral shedding from the lungs of the infected mice was evaluated by titration of the lung homogenates in MDCK cell culture on days 3 and 6 after infection. The level of specific antibodies to H7 avian influenza virus was determined by indirect enzyme immunoassay. Results: the use of Ad5-tet-M2NP adenovirus for immunisation of the mice ensured 100% survival of the animals that had disease symptoms (weight loss) after their infection with the lethal dose (5 LD50) of H7 avian influenza virus. The study demonstrated a high post-vaccination level of humoral immune response to H7 avian influenza virus. The virus titer decreased significantly by day 6 in the lungs of mice that had been immunised with Ad5-tet-M2NP compared to the control group. Conclusion: the Ad5-tetM2NP recombinant adenovirus can be used to create a candidate pandemic influenza vaccine that would protect against avian influenza viruses, subtype H7, in particular.


  • Open Access

    Immunogenic and protective properties of the recombinant human adenovirus serotype 5 expressing the glycoprotein G gene of the rabies virus vaccine strain RV-97

    by Federal Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, M.M. Shmarov, I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University), E.S. Sedova, A.E. Nikonova, A.L. Elakov, D.N. Shcherbinin, E.A. Artemova, E.S. Lebedeva, National Research Center – Institute of immunology of Federal Medico-Biological Agency, et al.